ImmunityBio Statistics

Total Valuation

ImmunityBio has a market cap or net worth of $3.55 billion. The enterprise value is $4.44 billion.

Market Cap	3.55B
Enterprise Value	4.44B

Important Dates

The last earnings date was Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

ImmunityBio has 696.83 million shares outstanding. The number of shares has increased by 54.09% in one year.

Current Share Class	696.83M
Shares Outstanding	696.83M
Shares Change (YoY)	+54.09%
Shares Change (QoQ)	+1.60%
Owned by Insiders (%)	42.40%
Owned by Institutions (%)	11.07%
Float	165.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	19.06
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	606.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.68

Current Ratio	2.68
Quick Ratio	2.22
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.41

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-56.35%
Return on Capital (ROIC)	-76.95%
Revenue Per Employee	$11,675
Profits Per Employee	-$935,978
Employee Count	628
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	-40,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +36.36% in the last 52 weeks. The beta is -0.43, so ImmunityBio's price volatility has been lower than the market average.

Beta (5Y)	-0.43
52-Week Price Change	+36.36%
50-Day Moving Average	4.27
200-Day Moving Average	5.28
Relative Strength Index (RSI)	54.10
Average Volume (20 Days)	7,203,569

Short Selling Information

The latest short interest is 52.75 million, so 7.57% of the outstanding shares have been sold short.

Short Interest	52.75M
Short Previous Month	51.58M
Short % of Shares Out	7.57%
Short % of Float	31.88%
Short Ratio (days to cover)	7.13

Income Statement

In the last 12 months, ImmunityBio had revenue of $7.33 million and -$587.79 million in losses. Loss per share was -$0.88.

Revenue	7.33M
Gross Profit	7.33M
Operating Income	-359.28M
Pretax Income	-601.00M
Net Income	-587.79M
EBITDA	-341.30M
EBIT	-359.28M
Loss Per Share	-$0.88

Full Income Statement

Balance Sheet

The company has $130.37 million in cash and $1.02 billion in debt, giving a net cash position of -$888.37 million or -$1.27 per share.

Cash & Cash Equivalents	130.37M
Total Debt	1.02B
Net Cash	-888.37M
Net Cash Per Share	-$1.27
Equity (Book Value)	-744.16M
Book Value Per Share	-1.07
Working Capital	102.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$421.36 million and capital expenditures -$12.73 million, giving a free cash flow of -$434.10 million.

Operating Cash Flow	-421.36M
Capital Expenditures	-12.73M
Free Cash Flow	-434.10M
FCF Per Share	-$0.62

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-4,900.22%
Pretax Margin	-8,018.55%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-136,703.97%

Dividends & Yields

ImmunityBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-54.09%
Shareholder Yield	-54.09%
Earnings Yield	-16.54%
FCF Yield	-12.21%

Analyst Forecast

The average price target for ImmunityBio is $17.38, which is 240.78% higher than the current price. The consensus rating is "Buy".

Price Target	$17.38
Price Target Difference	240.78%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmunityBio has an Altman Z-Score of -13.89 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.89
Piotroski F-Score	3